Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Alessio Mazzoni and Francesco Annunziato.
Alessio Mazzoni
Connection Strength
4.247
Francesco Annunziato
  1. Heterogeneous magnitude of immunological memory to SARS-CoV-2 in recovered individuals. Clin Transl Immunology. 2021; 10(5):e1281.
    View in: PubMed
    Score: 0.944
  2. Cell-mediated and humoral adaptive immune responses to SARS-CoV-2 are lower in asymptomatic than symptomatic COVID-19 patients. Eur J Immunol. 2020 Dec; 50(12):2013-2024.
    View in: PubMed
    Score: 0.912
  3. Eomes controls the development of Th17-derived (non-classic) Th1 cells during chronic inflammation. Eur J Immunol. 2019 01; 49(1):79-95.
    View in: PubMed
    Score: 0.796
  4. First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19. J Clin Invest. 2021 06 15; 131(12).
    View in: PubMed
    Score: 0.238
  5. The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection. Mucosal Immunol. 2021 03; 14(2):305-316.
    View in: PubMed
    Score: 0.229
  6. Quantitative and qualitative alterations of circulating myeloid cells and plasmacytoid DC in SARS-CoV-2 infection. Immunology. 2020 12; 161(4):345-353.
    View in: PubMed
    Score: 0.227
  7. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. J Clin Invest. 2020 09 01; 130(9):4694-4703.
    View in: PubMed
    Score: 0.225
  8. Musculin inhibits human T-helper 17 cell response to interleukin 2 by controlling STAT5B activity. Eur J Immunol. 2017 09; 47(9):1427-1442.
    View in: PubMed
    Score: 0.181
  9. Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib. Am J Hematol. 2021 11 01; 96(11):E408-E410.
    View in: PubMed
    Score: 0.060
  10. COVID-19 in a kidney transplant recipient after mRNA-based SARS-CoV-2 vaccination. Transpl Infect Dis. 2021 08; 23(4):e13649.
    View in: PubMed
    Score: 0.059
  11. Metabolomic/lipidomic profiling of COVID-19 and individual response to tocilizumab. PLoS Pathog. 2021 02; 17(2):e1009243.
    View in: PubMed
    Score: 0.058
  12. Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab. Immunol Lett. 2020 12; 228:122-128.
    View in: PubMed
    Score: 0.057
  13. Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study. Leukemia. 2021 04; 35(4):1121-1133.
    View in: PubMed
    Score: 0.056
  14. Prompt Predicting of Early Clinical Deterioration of Moderate-to-Severe COVID-19 Patients: Usefulness of a Combined Score Using IL-6 in a Preliminary Study. J Allergy Clin Immunol Pract. 2020 Sep; 8(8):2575-2581.e2.
    View in: PubMed
    Score: 0.055
  15. Th17 and Th1 Lymphocytes in Oligoarticular Juvenile Idiopathic Arthritis. Front Immunol. 2019; 10:450.
    View in: PubMed
    Score: 0.051
  16. Omalizumab dampens type 2 inflammation in a group of long-term treated asthma patients and detaches IgE from FceRI. Eur J Immunol. 2018 12; 48(12):2005-2014.
    View in: PubMed
    Score: 0.049
  17. Sphingosine Kinases promote IL-17 expression in human T lymphocytes. Sci Rep. 2018 09 05; 8(1):13233.
    View in: PubMed
    Score: 0.049
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.